Company profile: Spindle
1.1 - Company Overview
Company description
- Provider of proprietary RNA polymerase technology for large-scale mRNA vaccine production, and platforms that streamline mRNA manufacturing. Offerings include Linea IVT, combining Linea DNA IVT templates with the polymerase to reduce dsRNA impurities, and Linea DNA, an enzymatic, cell-free system for rapid production of high-fidelity DNA for therapeutic applications.
Products and services
- Proprietary RNA Polymerase: Powers large-scale mRNA vaccine production in IVT, pairing with Linea DNA IVT templates to streamline transcription and diminish dsRNA impurities
- Linea IVT: An IVT-based platform combining Linea DNA IVT templates with proprietary RNA polymerase to streamline mRNA production and yield lower dsRNA impurities during transcription
- Linea DNA: An enzymatically-produced, cell-free DNA platform delivering rapid generation of high-fidelity DNA sequences for diverse therapeutic applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Spindle
Lexicon Pharmaceuticals
HQ: United States
Website
- Description: Provider of precise medicines for human disease, including INPEFA (sotagliflozin), a once-daily oral tablet that reduces the risk of cardiovascular death, heart failure hospitalization and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. Pipeline includes LX9211 for DPNP (AAK1) and sotagliflozin for type 1 diabetes (US regulatory) and HCM (preclinical).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lexicon Pharmaceuticals company profile →
Lakewood-Amedex
HQ: United States
Website
- Description: Provider of novel anti-infective therapeutics for serious infectious diseases, including Bisphosphocins, a novel class of antimicrobial agents effective against a wide range of bacteria and fungi, including antibiotic-resistant strains; and Nu-3 gel, a Bisphosphocin gel for treating infected diabetic foot ulcers, advancing into Phase 2 clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lakewood-Amedex company profile →
Nebula Genomics
HQ: United States
Website
- Description: Provider of blockchain-enabled whole genome sequencing (30x and 100x coverage) and a trusted genomic and health data marketplace that ensures consumer data control. Offers Nebula Explore reporting membership, a curated research library, genome exploration tools, and deep genetic ancestry using full mtDNA and Y-DNA sequencing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nebula Genomics company profile →
Diagnoplex
HQ: Switzerland
Website
- Description: Provider of non-invasive colorectal cancer screening tests and diagnostics, including the COLOX colorectal cancer screening test; the company has conducted a 140-patient prospective pilot study demonstrating technical and clinical feasibility.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diagnoplex company profile →
Passage Bio
HQ: United States
Website
- Description: Provider of fully integrated gene therapy development focused on treatments for monogenic central nervous system diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Passage Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Spindle
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Spindle
2.2 - Growth funds investing in similar companies to Spindle
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Spindle
4.2 - Public trading comparable groups for Spindle
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →